Venetoclax

Generic Name
Venetoclax
Brand Names
Venclexta, Venclyxto
Drug Type
Small Molecule
Chemical Formula
C45H50ClN7O7S
CAS Number
1257044-40-8
Unique Ingredient Identifier
N54AIC43PW
Background

Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 . Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma . CLL is the most prevalent leu...

Indication

本品与阿扎胞苷联合用于治疗因合并症不适合接受强诱导化疗,或者年龄75岁及以上的新诊断的成人急性髓系白血病患者。

Associated Conditions
Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Associated Therapies
-

Activity and Safety of Front-line Venetoclax and Rituximab in Young and Fit Patients With Chronic Lymphocytic Leukemia

Phase 2
Completed
Conditions
Interventions
First Posted Date
2018-03-06
Last Posted Date
2023-11-24
Lead Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Target Recruit Count
77
Registration Number
NCT03455517
Locations
🇮🇹

Ao Di Perugia, Ospedale S. Maria Della Misericordia - Ematologia E Trapianto Midollo Osseo, Perugia, Italy

🇮🇹

Fondazione Policlinico Universitario Agostino Gemelli Irccs - Roma - Area Ematologica, Roma, Italy

🇮🇹

Università degli Studi di Roma "Sapienza", Roma, Italy

and more 28 locations

Venetoclax Add in Combination With Fludarabine, Cyratabine and Idarubicine in Induction for Acute Myelid Leukemia

Phase 2
Active, not recruiting
Conditions
Interventions
First Posted Date
2018-03-06
Last Posted Date
2024-04-10
Lead Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Target Recruit Count
124
Registration Number
NCT03455504
Locations
🇮🇹

Aou Senese - Uoc Ematologia E Trapianti, Siena, Italy

🇮🇹

Spedali Civili - Azienda Ospedaliera U.O. Ematologia, Brescia, Italy

🇮🇹

Asl Salerno, Presidio Ospedaliero Tortora Pagani - Ematologia, Pagani, Italy

and more 19 locations

A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia

First Posted Date
2018-02-22
Last Posted Date
2022-02-01
Lead Sponsor
AbbVie
Target Recruit Count
36
Registration Number
NCT03441555
Locations
🇩🇪

Univ Klinik Eppendorf Hamburg /ID# 168633, Hamburg, Germany

🇺🇸

NYU Langone Medical Center /ID# 201559, New York, New York, United States

🇺🇸

University of Pittsburgh Medic /ID# 170790, Pittsburgh, Pennsylvania, United States

and more 11 locations

Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib

First Posted Date
2018-02-05
Last Posted Date
2024-07-05
Lead Sponsor
Michael Choi
Target Recruit Count
24
Registration Number
NCT03422393
Locations
🇺🇸

UC San Diego Moores Cancer Center, La Jolla, California, United States

A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy

First Posted Date
2018-01-23
Last Posted Date
2024-08-06
Lead Sponsor
AbbVie
Target Recruit Count
120
Registration Number
NCT03406156
Locations
🇺🇸

Oncology Hematology Care, Inc. /ID# 202397, Cincinnati, Ohio, United States

🇺🇸

Tennessee Oncology-Nashville Centennial /ID# 201098, Nashville, Tennessee, United States

🇺🇸

Arizona Oncology Associates, PC-HOPE /ID# 202335, Tempe, Arizona, United States

and more 12 locations

Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients with Relapsed Multiple Myeloma

First Posted Date
2018-01-16
Last Posted Date
2024-11-04
Lead Sponsor
Mayo Clinic
Target Recruit Count
8
Registration Number
NCT03399539
Locations
🇺🇸

University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States

🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

🇺🇸

Siteman Cancer Center at Washington University, Saint Louis, Missouri, United States

Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL

First Posted Date
2017-12-20
Last Posted Date
2022-08-22
Lead Sponsor
TG Therapeutics, Inc.
Target Recruit Count
78
Registration Number
NCT03379051
Locations
🇺🇸

TG Therapeutics Investigational Trial Site, Cleveland, Ohio, United States

A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma

First Posted Date
2017-11-30
Last Posted Date
2023-02-08
Lead Sponsor
Calithera Biosciences, Inc
Target Recruit Count
43
Registration Number
NCT03357627
Locations
🇨🇦

Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada

🇺🇸

Ingalls Memorial Hospital, Harvey, Illinois, United States

🇨🇦

Jewish General Hospital, Montreal, Quebec, Canada

and more 12 locations
© Copyright 2024. All Rights Reserved by MedPath